Cargando…
Hyaluronic Acid-Based Medical Device for Treatment of Alveolar Osteitis—Clinical Study †
Alveolar Osteitis (AO) is a complication following the extraction of a tooth. AO manifests through localized pain in, and around, the extraction site, where the post-operative blood clot has been disintegrated. The aim of this single cohort study was to evaluate the outcome of a treatment of AO, usi...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801692/ https://www.ncbi.nlm.nih.gov/pubmed/31581430 http://dx.doi.org/10.3390/ijerph16193698 |
_version_ | 1783460636023324672 |
---|---|
author | Suchánek, Jakub Ivančaková, Romana Koberová Mottl, Radovan Browne, Klára Zoe Pilneyová, Kristýna Charlotte Pilbauerová, Nela Schmidt, Jan Suchánková Kleplová, Tereza |
author_facet | Suchánek, Jakub Ivančaková, Romana Koberová Mottl, Radovan Browne, Klára Zoe Pilneyová, Kristýna Charlotte Pilbauerová, Nela Schmidt, Jan Suchánková Kleplová, Tereza |
author_sort | Suchánek, Jakub |
collection | PubMed |
description | Alveolar Osteitis (AO) is a complication following the extraction of a tooth. AO manifests through localized pain in, and around, the extraction site, where the post-operative blood clot has been disintegrated. The aim of this single cohort study was to evaluate the outcome of a treatment of AO, using a pharmacological device composed of hyaluronic acid and octenidine dihydrochloride. The tested device is a sponge-like material, composed solely of a fully dissoluble medicaments (hyaluronic acid, calcium chloride, and octenidine dihydrochloride). It was designed to serve as a non-toxic, slow-dissolving antiseptic, that adheres to mucosa and obturates the wound. This study includes 58 subjects who were diagnosed with AO. The tested device was administered once daily until local pain subsided to < 20 mm of the Visual Analog Scale (VAS). The treatment was considered effective when the pain subsided to < 20 mm VAS in < 8 days of treatment; as per comparative studies. Our findings provide a statistically significant success rate of 96.0% (95.0% confidence interval of 75.75% to 97.8%) after pharmacological device administrations. No adverse medical effects were detected. Acquired data confirmed that lyophilized hyaluronic acid, combined with octenidine, is effective for the treatment of AO. The results are clinically important as AO is a common complication after third molar extractions. |
format | Online Article Text |
id | pubmed-6801692 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-68016922019-10-31 Hyaluronic Acid-Based Medical Device for Treatment of Alveolar Osteitis—Clinical Study † Suchánek, Jakub Ivančaková, Romana Koberová Mottl, Radovan Browne, Klára Zoe Pilneyová, Kristýna Charlotte Pilbauerová, Nela Schmidt, Jan Suchánková Kleplová, Tereza Int J Environ Res Public Health Article Alveolar Osteitis (AO) is a complication following the extraction of a tooth. AO manifests through localized pain in, and around, the extraction site, where the post-operative blood clot has been disintegrated. The aim of this single cohort study was to evaluate the outcome of a treatment of AO, using a pharmacological device composed of hyaluronic acid and octenidine dihydrochloride. The tested device is a sponge-like material, composed solely of a fully dissoluble medicaments (hyaluronic acid, calcium chloride, and octenidine dihydrochloride). It was designed to serve as a non-toxic, slow-dissolving antiseptic, that adheres to mucosa and obturates the wound. This study includes 58 subjects who were diagnosed with AO. The tested device was administered once daily until local pain subsided to < 20 mm of the Visual Analog Scale (VAS). The treatment was considered effective when the pain subsided to < 20 mm VAS in < 8 days of treatment; as per comparative studies. Our findings provide a statistically significant success rate of 96.0% (95.0% confidence interval of 75.75% to 97.8%) after pharmacological device administrations. No adverse medical effects were detected. Acquired data confirmed that lyophilized hyaluronic acid, combined with octenidine, is effective for the treatment of AO. The results are clinically important as AO is a common complication after third molar extractions. MDPI 2019-10-01 2019-10 /pmc/articles/PMC6801692/ /pubmed/31581430 http://dx.doi.org/10.3390/ijerph16193698 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Suchánek, Jakub Ivančaková, Romana Koberová Mottl, Radovan Browne, Klára Zoe Pilneyová, Kristýna Charlotte Pilbauerová, Nela Schmidt, Jan Suchánková Kleplová, Tereza Hyaluronic Acid-Based Medical Device for Treatment of Alveolar Osteitis—Clinical Study † |
title | Hyaluronic Acid-Based Medical Device for Treatment of Alveolar Osteitis—Clinical Study † |
title_full | Hyaluronic Acid-Based Medical Device for Treatment of Alveolar Osteitis—Clinical Study † |
title_fullStr | Hyaluronic Acid-Based Medical Device for Treatment of Alveolar Osteitis—Clinical Study † |
title_full_unstemmed | Hyaluronic Acid-Based Medical Device for Treatment of Alveolar Osteitis—Clinical Study † |
title_short | Hyaluronic Acid-Based Medical Device for Treatment of Alveolar Osteitis—Clinical Study † |
title_sort | hyaluronic acid-based medical device for treatment of alveolar osteitis—clinical study † |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801692/ https://www.ncbi.nlm.nih.gov/pubmed/31581430 http://dx.doi.org/10.3390/ijerph16193698 |
work_keys_str_mv | AT suchanekjakub hyaluronicacidbasedmedicaldevicefortreatmentofalveolarosteitisclinicalstudy AT ivancakovaromanakoberova hyaluronicacidbasedmedicaldevicefortreatmentofalveolarosteitisclinicalstudy AT mottlradovan hyaluronicacidbasedmedicaldevicefortreatmentofalveolarosteitisclinicalstudy AT browneklarazoe hyaluronicacidbasedmedicaldevicefortreatmentofalveolarosteitisclinicalstudy AT pilneyovakristynacharlotte hyaluronicacidbasedmedicaldevicefortreatmentofalveolarosteitisclinicalstudy AT pilbauerovanela hyaluronicacidbasedmedicaldevicefortreatmentofalveolarosteitisclinicalstudy AT schmidtjan hyaluronicacidbasedmedicaldevicefortreatmentofalveolarosteitisclinicalstudy AT suchankovakleplovatereza hyaluronicacidbasedmedicaldevicefortreatmentofalveolarosteitisclinicalstudy |